Eton Pharmaceuticals Accelerates Rare-Disease Portfolio with Increlex and Amglidia Acquisitions, Eyes 16-Product Line
Eton Pharmaceuticals (NASDAQ: ETON) announced that it has closed two acquisitions this quarter, adding the Increlex and ...
Read story →